Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Consolidated Net Income (2020 - 2026)

Tango Therapeutics has reported Consolidated Net Income over the past 6 years, most recently at -$38.7 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 2.86% year-over-year to -$38.7 million; the TTM value through Dec 2025 reached -$101.6 million, up 22.03%, while the annual FY2025 figure was -$101.6 million, 22.03% up from the prior year.
  • Consolidated Net Income for Q4 2025 was -$38.7 million at Tango Therapeutics, down from $15.9 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $15.9 million in Q3 2025 and troughed at -$39.9 million in Q1 2025.
  • A 5-year average of -$25.0 million and a median of -$26.8 million in 2023 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: crashed 951806.78% in 2021 and later soared 154.46% in 2025.
  • Year by year, Consolidated Net Income stood at -$22.1 million in 2021, then crashed by 31.77% to -$29.1 million in 2022, then dropped by 5.82% to -$30.8 million in 2023, then dropped by 22.5% to -$37.7 million in 2024, then fell by 2.86% to -$38.7 million in 2025.
  • Business Quant data shows Consolidated Net Income for TNGX at -$38.7 million in Q4 2025, $15.9 million in Q3 2025, and -$38.9 million in Q2 2025.